Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 15, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 16, 2026.
Predicted vs. what happened
What happened
Reached its target in 85 days.
The thesis — published February 15, 2026
Short-term idea: early prescription activity and a big capital injection make the company more likely to hit execution milestones and attract investor attention. That can lift the stock, but biotech headlines and overall sector mood can make the price swing a lot, so buy in stages and wait for the price to stop falling before adding.
Primary drivers
- Early prescriptions show the product launch may be working
- New funding reduces the near-term need for more money
- Upcoming trial and program updates can give the stock news to move on
- Investor appetite for biotech can quickly push the stock up or down
How it played out
ARWR: target reached in 85 days
Lyra published ARWR at $63.82 on 2026-02-15, with expected growth of 25% and a target of $79.78. The thesis pointed to early prescription activity, new funding, upcoming trial and program updates, and investor appetite for biotech as the setup for a short-term move. It also noted that the price could swing a lot.
Inside the window, ARWR reached a peak of $82 on 2026-05-14. That was above the $79.78 target, with a peak gain of 28.5%. The target was reached in 85 days. The stock ended the window at $76.67. The thesis played out.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.